Advertisement
Advertisement
U.S. markets open in 4 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bluejay Diagnostics, Inc. (BJDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.5384+0.0158 (+3.02%)
At close: 04:00PM EDT
0.3960 -0.14 (-26.45%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close0.5226
Open0.5010
Bid0.3250 x 1200
Ask0.4499 x 3000
Day's Range0.5010 - 0.5734
52 Week Range0.2780 - 1.8300
Volume147,226
Avg. Volume117,954
Market Cap10.85M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BJDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bluejay Diagnostics, Inc.
    Daily – Vickers Top Insider Picks for 05/05/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • GlobeNewswire

    Bluejay Diagnostics Reports 2022 Financial Results

    ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the year ended December 31, 2022. “Significant developmental strides were made during 2022, with our IL-6 clinical study data affirming the potential of Bluejay’s Symphony System to be a r

  • GlobeNewswire

    Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

    ACTON, Mass. and WEST WARWICK, R.I., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets. As part of the agreement, Bluejay will be recognized as a strategic partner of BCA member organizations, with BCA referring strategic group purch

  • GlobeNewswire

    Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

    ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’s Symphony IL-6 test by directly engaging the

Advertisement
Advertisement